Derek Jantz - Precision BioSciences Chief CoFounder
| DTIL Stock | USD 7.11 0.25 3.64% |
Insider
Derek Jantz is Chief CoFounder of Precision BioSciences
| Age | 48 |
| Address | 302 East Pettigrew Street, Durham, NC, United States, 27701 |
| Phone | 919 314 5512 |
| Web | https://www.precisionbiosciences.com |
Precision BioSciences Management Efficiency
The company has return on total asset (ROA) of (0.0638) % which means that it has lost $0.0638 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2444 %, meaning that it created $0.2444 on every $100 dollars invested by stockholders. Precision BioSciences' management efficiency ratios could be used to measure how well Precision BioSciences manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.4. The value of Return On Capital Employed is expected to slide to -0.42. At this time, Precision BioSciences' Fixed Asset Turnover is quite stable compared to the past year. Asset Turnover is expected to rise to 0.32 this year, although the value of Other Assets will most likely fall to 0.95.Similar Executives
| Showing other executives | INSIDER Age | ||
| Marc MD | Alector | 50 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Bill DeGrado | Pliant Therapeutics | N/A | |
| James Spudich | Cytokinetics | 82 | |
| David Pompliano | Revolution Medicines | N/A | |
| Gene Kim | Dyne Therapeutics | 47 | |
| Kari JD | Cytokinetics | N/A | |
| MA MS | Inozyme Pharma | N/A | |
| Christine MBA | Hookipa Pharma | 59 | |
| MS MD | Dyne Therapeutics | 57 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Sergey MD | Black Diamond Therapeutics | 55 | |
| Marine Popoff | Hookipa Pharma | N/A | |
| Peter Heutink | Alector | N/A | |
| Michael Fischbach | Revolution Medicines | 43 | |
| Alexandra HughesWilson | Mereo BioPharma Group | 53 | |
| Craig Muir | Pliant Therapeutics | N/A | |
| David Hovland | Eledon Pharmaceuticals | N/A | |
| ric MD | Pliant Therapeutics | 60 | |
| Johannes Hull | Pliant Therapeutics | 49 | |
Management Performance
| Return On Equity | 0.24 | ||||
| Return On Asset | -0.0638 |
Precision BioSciences Leadership Team
Elected by the shareholders, the Precision BioSciences' board of directors comprises two types of representatives: Precision BioSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Precision. The board's role is to monitor Precision BioSciences' management team and ensure that shareholders' interests are well served. Precision BioSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Precision BioSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maurissa Messier, Senior Communications | ||
| Derek Jantz, Chief CoFounder | ||
| Jefferson Smith, CoFounder Officer | ||
| Bruce Stevens, Vice Compliance | ||
| John Kelly, Chief Officer | ||
| Dario JD, General Secretary | ||
| Juli Blanche, Chief Officer | ||
| Garrett Gincley, Head Manufacturing | ||
| Mei Burris, Director Finance | ||
| Cindy Atwell, Chief Officer | ||
| Neil MS, Manufacturing Chemistry | ||
| John RPh, CFO Officer | ||
| Alan MD, Chief Officer | ||
| Heather King, Director PR | ||
| Michael Amoroso, CEO President | ||
| Shane Barton, Co VP | ||
| Naresh Tanna, Chief Relations | ||
| Dario Scimeca, General Secretary |
Precision Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Precision BioSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | ||||
| Return On Asset | -0.0638 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | (36.94) % | ||||
| Current Valuation | (18.27 M) | ||||
| Shares Outstanding | 7.67 M | ||||
| Shares Owned By Insiders | 6.50 % | ||||
| Shares Owned By Institutions | 44.70 % | ||||
| Number Of Shares Shorted | 214.55 K | ||||
| Price To Earning | (6.10) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.4 | Revenue Per Share 12.872 | Quarterly Revenue Growth (0.96) | Return On Assets (0.06) | Return On Equity 0.2444 |
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.